The Evaluation of Injection Site Pain and Adherence in Patients Switching from a Low to High Concentration Adalimumab (AVT-02) Across Multiple Indications.

Active, not recruitingOBSERVATIONAL

Enrollment

600

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

December 18, 2024

Study Completion Date

May 13, 2025

Conditions

Crohn DiseaseUlcerative ColitisRheumatoid ArthritisAnkylosing SpondylitisPsoriatic ArthritisPlaque PsoriasisHidradenitis Suppurativa

Interventions

BIOLOGICAL

AVT02 (Alvotech Biosimilar to Adalimumab)

Phase IV Study

Trial Locations (1)

JAMP Pharma Corporation, Montreal